Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.

ABSTRACT:

SUBMITTER: Mistry R 

PROVIDER: S-EPMC10398120 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature